Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | TOP2A | P11388 | 3/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697390 | 0.88 | CACNA1H (0.35) | CACNA1HCACNA1BPTPN1BCHEACHE | |
| SCHEMBL4694071 | 0.82 | SIGMAR1 (0.33) | CACNA1HCACNA1B | |
| SCHEMBL5233167 | 0.81 | CACNA1H (0.32) | CACNA1HCACNA1B | |
| SCHEMBL4693268 | 0.81 | LMNA (0.35) | ACHEALDH1A1MAPK1HSD17B10 | |
| SCHEMBL4695703 | 0.79 | CACNA1H (0.34) | CACNA1HCACNA1BPTPN1BCHEACHE | |
| SCHEMBL6322408 | 0.78 | CACNA1H (0.36) | CACNA1HCACNA1BBCHEACHEMAOB | |
| SCHEMBL4695750 | 0.76 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL4692972 | 0.76 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL4695304 | 0.76 | SLC6A2 (0.33) | MAPK1 | |
| SCHEMBL4692912 | 0.75 | LMNA (0.30) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684749-B1 | USE OF 1,3-DIAZA-DIBENZO[e,h] AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2007-09-05 | — | — | EP | claimed |